How effective is rituximab for lymphoma?
The use of rituximab for lymphoma is generally considered to be effective in increasing the life of the affected patients. Generally, the use of rituximab is associated with non-hodgkin lymphoma, and when patients receive doses of drugs, their lifetime increases compared to similar patients who did not receive treatment. Despite these positive initial findings, the use of rituximab for lymphoma has some serious related side effects, including liver failure, kidney problems and even death. The drug is generally prescribed only if it has been shown for a particular patient that other treatment is ineffective.
Lymphoma cancer affects lymphocyte cells of the lymphatic system that is associated with the human immune system. There are many types of lymphoma. All affect B and T cells that usually fight infections in the body. The lymphoma of non-hodgkins is a specific type of lymphoma that usually occurs in adults and generally affects 2 percent of all people. This cancer is significantly more common if the patient hasAn already weakened immune system.
classified as a monoclonal antibody, rituximab is administered intravenously, usually for the treatment of rheumatoid arthritis or non-hodgkin lymphoma. Rituximab for lymphoma is an artificial antibody that has been developed by cloned human and mouse or rats. The drug comes in disposable bottles consisting of 100 milligrams or 500 milligrams and must be mixed with another liquid before administration. Other treatment for the same rituximab classification include trastuzumab and gemtuzumab ozogamicin.
Rituximab for lymphoma works by connecting to receptors on the outside of the tumor and then trying to break it. Most tumor cells of non-hodgkins lymphoma include a receptor called CD20, which is focused on the drug. It is usually influenced by recipes that combine and cause to grow or even multiply the tumor. To reduce the size of the Ritux tumorIMAB basically causes it to disintegrate when it connects to the CD20 receptor.
lymphoma non-hodgkins has several forms and rituximab is usually used in patients with follicular lymphoma, which is common diversity. Many studies have been performed in the effects of the drug. Most research focuses on the use of rituximab as maintenance therapy, which means that patients cancer is in remission when starting treatment. Scientific studies suggest that patients treated with rituximab had a better overall survival than those who were not treated with any maintenance therapy.